Publications by authors named "B Pegourie"

Claim this Profile
A
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Carmen Aanei, Michel Ticchioni, Brigitte Pegourie

Blood· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.
Frank Bridoux, Bertrand Arnulf, Lionel Karlin, Nicolas Blin, Nolwenn Rabot, Brigitte Pegourie

J Clin Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.
Maroulio Pertesi, Maxime Vallée, Xiaomu Wei, Maria V Revuelta, Perrine Galia, Brigitte Pegourie

Leukemia· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Anne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, Valerie Rouille, Beatrice Mahe, Brigitte Pegourie

Lancet Haematol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Brigitte Pegourie, Lionel Karlin, Lotfi Benboubker, Frédérique Orsini-Piocelle, Mourad Tiab

Am J Hematol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis